Exosomes derived from bone marrow mesenchymal stem cells promote osteosarcoma development by activating oncogenic autophagy

•BMSC-Exos promote malignant tumorigenesis and metastasis in OS cells.•BMSC-Exos promotes oncogenic autophagy in OS cells.•BMSC-Exos-mediated autophagy contributes to the BMSC-Exos-induced malignant tumorigenesis metastasis in OS cells. Osteosarcoma (OS) is a malignant bone tumor that frequently occ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of bone oncology 2020-04, Vol.21, p.100280-100280, Article 100280
Hauptverfasser: Huang, Yao, Liu, Wei, He, Bing, Wang, Lei, Zhang, Fucheng, Shu, Hao, Sun, Luning
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•BMSC-Exos promote malignant tumorigenesis and metastasis in OS cells.•BMSC-Exos promotes oncogenic autophagy in OS cells.•BMSC-Exos-mediated autophagy contributes to the BMSC-Exos-induced malignant tumorigenesis metastasis in OS cells. Osteosarcoma (OS) is a malignant bone tumor that frequently occurs in adolescents. It has a high rate of pulmonary metastasis and mortality. Previous studies have demonstrated that human bone marrow mesenchymal stem cells (hBMSCs) can promote the malignant progression in various tumors, including OS. Also, it is recognized that exosomes derived from hBMSCs (hBMSC-Exos) mediate cell-to-cell communication and exhibit similar effects on the development of various tumors. However, the role of hBMSC-Exos in the development of OS is still unclear and the underlying mechanism needs to be elucidated. Our results show that hBMSC-derived exosomes promote OS cell proliferation, migration, and invasion. Meanwhile, silencing autophagy-related gene 5 (ATG5) in OS cells abolishes the pro-tumor effects of hBMSC-Exos in vitro and in vivo. Our present study demonstrates that hBMSC-Exos promotes tumorigenesis and metastasis by promoting oncogenic autophagy in OS.
ISSN:2212-1374
2212-1366
2212-1374
DOI:10.1016/j.jbo.2020.100280